Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Low-grade NMIBC|FGFR Gene Amplification|FGFR Gene Alterations|FGFR3 Gene Alteration|FGFR3 Gene Mutation|FGFR3 Gene Fusions
DRUG: TYRA-300 60mg|DRUG: TYRA-300 50mg|DRUG: TYRA-300 Dose TBD
To assess the efficacy of TYRA-300 in LG IR-NMIBC participants, Complete response (CR) rate, at 3 months
Duration of response (responders only), time from initial response to confirmed recurrence of disease or death, up to 24 months|Time to recurrence (responders only), time from start of response to confirmed recurrence of disease, up to 24 months|Recurrence-free survival rate (responders only), at 12 months and 24 months|Progression-free survival (all participants), time from randomization to the progression of disease or death from any cause, whichever occurs first, up to 24 months|Incidence and severity of adverse events, Up to 2 years|To assess the safety and tolerability of TYRA-300 in LG IR-NMIBC participants, Assessed by adverse events, From initiation of treatment to 2 years
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer